trustme.bro/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim
Pharmaceutical drug names follow systematic nomenclature rules set by regulatory authorities and the INN
the verdict
SUPPORTED
the evidence backs this
refutedsupported
the weight of evidence
2 sources for · 0 against

Pharmaceutical drug names follow systematic nomenclature rules and guidelines established by regulatory authorities and international bodies such as the World Health Organization's INN program.

Evidence for · 2
Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names.
2022 · cited by 24
Discusses the assignment of international nonproprietary names (INNs) by the World Health Organization to therapeutic antibodies based on systematic molecular analysis and nomenclature.
See more details
The analysis

The claim states that pharmaceutical drug names follow systematic nomenclature rules set by regulatory authorities and the INN. Retrieved papers [3] and [11] explicitly discuss the assignment and systematic analysis of International Nonproprietary Names (INNs) by the World Health Organization and regulatory standards, fully supporting the claim. No papers refute this.

More for · 1
The harmonization of World Health Organization International Nonproprietary Names definitions for cell and cell-based gene therapy substances: when a name is not enough
2021 · cited by 6
Details how the World Health Organization assigns International Nonproprietary Names (INNs) to pharmaceutical substances following specific nomenclature rules and definitions.
Everything we examined (12)
We also searched for evidence AGAINST this claim, not only for it.
  1. Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape.peer-reviewedno side takennot shown: read and judged not to bear on this claim
  2. Practice Guidelines for Ocular Telehealth-Diabetic Retinopathy, Third Edition.peer-reviewedno side takennot shown: read and judged not to bear on this claim
  3. Current Understanding and Translational Prospects of Tetrahedral Framework Nucleic Acids.peer-reviewedno side takennot shown: read and judged not to bear on this claim
  4. Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names.peer-reviewedsupports
  5. Global Substance Registration System: consistent scientific descriptions for substances related to health.peer-reviewedno side takennot shown: read and judged not to bear on this claim
  6. Data Interoperability for Ambulatory Monitoring of Cardiovascular Disease: A Scientific Statement From the American Heart Association.peer-reviewedno side takennot shown: read and judged not to bear on this claim
  7. Evaluation of Physicians' Knowledge and Attitudes Towards Biosimilars in Russia and Issues Associated with Their Prescribing.peer-reviewedno side takennot shown: read and judged not to bear on this claim
  8. Assessment of pharmacists' views on biosimilar naming conventions.peer-reviewedno side takennot shown: read and judged not to bear on this claim
  9. An update on the clinical evidence that supports biosimilar approvals in Europe.peer-reviewedno side takennot shown: read and judged not to bear on this claim
  10. Real-World Evidence in New Drug and Biologics License Application Approvals During Fiscal Years 2020–2022peer-reviewedno side takennot shown: read and judged not to bear on this claim
  11. Similar biologics in India: A story of access or potential for compromise?peer-reviewedno side takennot shown: read and judged not to bear on this claim
  12. The harmonization of World Health Organization International Nonproprietary Names definitions for cell and cell-based gene therapy substances: when a name is not enoughpeer-reviewedsupports
The paper trail · every fact has a biography
first checked05 Aug 2026
judged → SUPPORTED · 7205 Aug 2026
This receipt carries no identity, shared or not. Sharing publishes your connection to it, not your data.
Check your own claim
Challenge the receipt
trust me, bro: win the argument, pass the class, survive peer review.
This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work · Dispute this receipt